The global atopic dermatitis treatment market is projected to grow at a considerable CAGR of around 6% during the forecast period (2020-2026). Genes and outer environment are the two factors responsible for the atopic dermatitis disorder. According to the National Institute of Allergy and Infectious Diseases, atopic dermatitis is an inflammatory skin condition that affects nearly 30% of the US population, mostly children and adolescents. The high prevalence of atopic disorder is a key factor driving the growth of the market across the globe. 

Additionally, the increase in the per capita healthcare expenditure along with the reach to the enhanced health insurance coverage is further promoting the growth of the atopic dermatitis market across the globe. The increase in the investment related to the R&D of the researches related to the skin-related disorders is further making a huge contribution towards the growth of the atopic dermatitis treatment market. However, higher costs associated with the R&D and the development of new drugs skin-related to hinder the growth of the global market. 

Segmental Outlook  

The atopic dermatitis treatment market is segmented on the basis of drug class and route of administration. Based on the drug class, the atopic dermatitis market is segmented into corticosteroids, emollients, PDE-4 inhibitors, calcineurin inhibitors, antibiotics, and others. Corticosteroids are expected to hold considerable market share based on drug class. Corticosteroids are used in the treatment of itching, swelling, allergic reactions, and redness. The high usage of this drug to treat the pain related to the inflammation in the body is driving the high growth of this market segment. Based on the route of administration, the market is segmented into oral, topical, and injectable. Topical is anticipated to hold major market share based on the route of the administration. 

Topical to be considerable growth potential  

Topical is the highly preferred route of administration for the treatment of atopic dermatitis. Atopic dermatitis is much common in children in comparison to the adults. The ease of administration of this route is creating a high demand for this market segment. 

Global Atopic Dermatitis Treatment Market Share by Route of Administration, 2019 (%)

Regional Outlook 

The global atopic dermatitis treatment market is further segmented on the basis of geography including North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to hold a considerable market share during the forecast period. The rising prevalence of atopic disorder, high healthcare spending, and the presence of cohesive government policies for R&D related to the atopic dermatitis treatment is anticipated to be the key factors contributing towards the high share of the North America region. Europe is another region holding a considerable position in the global atopic disorder market. The availability of huge funding for the research related to the treatment of derma related disorders is anticipated to make a huge contribution towards the high share of the market in the region.

Global Atopic Dermatitis Treatment Market Growth, by Region 2020-2026

Asia-Pacific to exhibit considerable growth during the forecast period 2020-2026

The rapidly evolving healthcare infrastructure, growing per capita healthcare expenditure, along with the presence of huge targeted patient pool is anticipated to be the key factors driving the growth of the atopic dermatitis treatment market in the Asia-Pacific region. In addition, a significant rise in the generic drugs for the atopic dermatitis treatment is further making a huge contribution towards the high growth of the emerging countries of the region such as India, China, and South Korea. However, the presence of underdeveloped healthcare infrastructure may restrain the growth of the market in some slow growth economies of the Asia-Pacific region. 

Market Players Outlook

The atopic dermatitis treatment market is a consolidated market thereby creating huge entry barriers for the new entrants in the market. The major players of the atopic dermatitis market include Pfizer, Inc., LEO Pharma A/S, Mylan N.V., Bausch Health Companies Inc., Bayer HealthCare AG, Encore Dermatology, Inc., AbbVie Inc., Allergan PLC, GlaxoSmithKline PLC, and so on. These players are actively adopting different growth strategies such as new product launch, partnerships, collaboration, and mergers and acquisition among others to remain competitive in the marketplace.  Moreover, the market players are making hefty investments in the R&D of new drugs for the launch of more effective drugs. For instance, in March 2018, Sanofi SA received FDA approval for Dupixent (Dupilumab), the first biologic drug approved for patients with moderate-to-severe atopic dermatitis. 

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global atopic dermatitis treatment market. Based on the availability of data, information related to the products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.